Search
Now showing items 1-6 of 6
Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
(
Wiley Open Access
, 2019 , Article)
Salivary duct carcinoma (SDC) is a rare, aggressive salivary gland malignancy, which often presents at an advanced stage. A proportion of SDC are characterized by HER2 amplification and/or overexpression of androgen receptor ...
Molecular characterization of cancers with NTRK gene fusions
(
Springer Nature
, 2019 , Article)
Targeted inhibitors of neurotropic tyrosine kinases are highly effective in selected patients with gene fusions involving NTRK1, NTRK2, or NTRK3. These fusions are consistently detected in rare cancer types (e.g., secretory ...
Abstract B094: Novel method for patient stratification in breast carcinoma based upon spatial analysis of tumor microenvironment
(
American Association for Cancer Research
, 2019 , Conference Paper)
Breast cancer consists of several intrinsic molecular subtypes, providing the basis for clinical treatment decisions. Lately, it is becoming increasingly recognized that factors other than the intrinsic cancer characteristics, ...
Immunohistochemistry-Enabled Precision Medicine
(
Springer, Cham
, 2019 , Book chapter)
Immunohistochemistry (IHC) can be applied to diagnostic aspects of pathologic examination to provide aid in assignment of lineage and histologic type of cancer. Increasingly, however, IHC is widely used to provide prognostic ...
Theranostic molecular profiling of pleomorphic ductal carcinoma of the breast.
(
Wiley
, 2019 , Other)
Pleomorphic ductal carcinoma (PDC) is a very rare subtype of invasive ductal carcinoma of no‐special type (NST), characterized by the presence of highly atypical/bizarre (>6‐fold variation in nuclear size) and multinucleated ...
Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer.
(
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
, 2019 , Article Review)
The treatment of several solid and hematologic malignancies with immune checkpoint inhibitors (against PD-1/PD-L1) has dramatically changed the cancer treatment paradigm. However, no checkpoint inhibitors were previously ...